Updates Delayed on Regenxbio’s CLN2 Gene Therapy Programs

Updates Delayed on Regenxbio’s CLN2 Gene Therapy Programs

294197

Updates Delayed on Regenxbio’s CLN2 Gene Therapy Programs

Regenxbio plans to provide updates on its RGX-181 and RGX-381 gene therapy candidates for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease, in the second half of this year. The company is currently reviewing information requests from the U.S. Food and Drug Administration (FDA), related to a clinical hold the agency placed on a proposed trial of RGX-181, after the company submitted an investigational new drug (IND)…

You must be logged in to read/download the full post.